IFIH1 and lymphoma: Distinct immune “families” are already emerging: interferon-driven diseases (anti-MDA5, anti-Ro52, anti-RNP), fibrotic-matrix disorders (anti–topoisomerase I, anti-Th/To, anti-PM/Scl), vasculopathic or complement-amplified syndromes (anti-C1q, antiphospholipid antibodies), onco-immune clusters (anti–RNA polymerase III, anti-TIF1γ), and B-cell hyperplastic phenotypes (high-titer anti-Ro52 Sjögren’s with lymphoma risk) [175].